Mark Sheptoff Financial Planning LLC Raises Stake in DexCom, Inc. (NASDAQ:DXCM)

Mark Sheptoff Financial Planning LLC increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,435 shares of the medical device company’s stock after buying an additional 300 shares during the period. Mark Sheptoff Financial Planning LLC’s holdings in DexCom were worth $674,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Stableford Capital II LLC increased its stake in DexCom by 2.1% in the 4th quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after purchasing an additional 88 shares during the period. D Orazio & Associates Inc. increased its stake in shares of DexCom by 0.8% in the fourth quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock worth $1,534,000 after buying an additional 93 shares during the period. EverSource Wealth Advisors LLC raised its holdings in DexCom by 10.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock valued at $133,000 after buying an additional 98 shares during the last quarter. Valley National Advisers Inc. boosted its position in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the period. Finally, FORVIS Wealth Advisors LLC grew its holdings in DexCom by 0.7% in the 4th quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock worth $2,033,000 after acquiring an additional 110 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In other news, CFO Jereme M. Sylvain sold 11,661 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total value of $1,567,355.01. Following the completion of the sale, the chief financial officer now directly owns 85,534 shares in the company, valued at approximately $11,496,624.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the transaction, the chief executive officer now directly owns 333,526 shares in the company, valued at $44,479,027.36. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Jereme M. Sylvain sold 11,661 shares of the firm’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total transaction of $1,567,355.01. Following the sale, the chief financial officer now owns 85,534 shares in the company, valued at $11,496,624.94. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 186,641 shares of company stock worth $25,217,707. 0.30% of the stock is owned by company insiders.

DexCom Stock Performance

Shares of DXCM stock traded down $4.51 on Thursday, reaching $126.02. The stock had a trading volume of 956,466 shares, compared to its average volume of 2,868,030. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The stock has a market cap of $50.12 billion, a P/E ratio of 84.21, a price-to-earnings-growth ratio of 3.20 and a beta of 1.23. The company has a 50 day simple moving average of $133.10 and a 200 day simple moving average of $123.99.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. Equities research analysts expect that DexCom, Inc. will post 1.78 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. UBS Group upped their price objective on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Canaccord Genuity Group raised their price objective on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research report on Friday, May 17th. Citigroup increased their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, Raymond James lifted their target price on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $141.67.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.